Alzheimer’s disease takes its name from Alois Alzheimer, a German psychiatrist and neuroanatomist who, in 1906, presented the first detailed clinical and pathological description of the condition that would eventually bear his name. The term itself, though, was not his doing. It was coined four years later by Emil Kraepelin, one of the most influential psychiatrists of the era, who inserted “Alzheimer’s disease” into his widely read textbook. The story behind that naming is tangled up with institutional politics, overlooked rivals, and a decades-long debate about what the disease actually was.
The Patient Who Started Everything
In November 1901, a 50-year-old woman named Auguste Deter was admitted to the Institution for the Mentally Ill and for Epileptics in Frankfurt, Germany. Her husband described a rapid and bewildering decline: memory loss, paranoia, disorientation, and unpredictable aggression. She could not recall recent events, hid objects, and sometimes screamed for hours. Her attending physician was Alois Alzheimer, then a 37-year-old clinician with a deep interest in brain pathology. Alzheimer conducted extensive interviews with Deter, documenting her symptoms in meticulous notes that still survive. He followed her case from admission through progressive sleep disturbance, confusion, and worsening aggression until her death five years later, in April 1906.1PubMed Central. The discovery of Alzheimer’s disease
What made this case unusual for the time was Deter’s age. Severe dementia was expected in very old people and had been described for centuries under terms like “senile dementia” or simply “senility.” But Deter was relatively young. Her rapid cognitive collapse did not fit the prevailing understanding of age-related mental decline, and Alzheimer sensed that something biologically distinct was happening.
The 1906 Presentation and What Alzheimer Saw
After Deter’s death, Alzheimer obtained her brain and examined it using a silver staining technique known as the Bielschowsky method, which was capable of revealing fine structural details in nerve tissue. The technique could highlight both the protein deposits between nerve cells and the tangled fibers inside them, making it uniquely suited for the kind of pathology Alzheimer was looking for.2PubMed. New temperature modification makes the Bielschowsky silver stain reproducible
What he found under the microscope was striking. The brain showed extensive cell loss along with two abnormal features: dense clumps of material scattered between neurons, and thick, twisted bundles of fibers inside the neurons themselves. Today these are known as amyloid plaques and neurofibrillary tangles, the twin hallmarks of the disease. At the time, neither had a name, but Alzheimer recognized them as unusual and likely related to Deter’s symptoms.
On November 3, 1906, Alzheimer presented his findings under the title “A peculiar severe disease process of the cerebral cortex” at the 37th Meeting of South-West German Psychiatrists in Tübingen.1PubMed Central. The discovery of Alzheimer’s disease The talk was brief, likely only about ten minutes, and the response from the audience was underwhelming. According to historical accounts, there were no questions and no discussion afterward. The assembled psychiatrists were reportedly more interested in a separate presentation about compulsive masturbation. Alzheimer’s meticulous clinicopathological case report, which would later reshape the understanding of dementia, landed with a thud.
How the Name Came to Be
If the broader psychiatric community was unmoved, one person was not: Emil Kraepelin. Kraepelin was Alzheimer’s boss and mentor at the Royal Psychiatric Clinic in Munich, and he was arguably the most powerful figure in German psychiatry. He was in the middle of revising his landmark textbook, Psychiatrie, which functioned as a kind of authoritative classification system for mental illness across Europe. In the 1910 eighth edition, Kraepelin included a new entry for “Alzheimer’s disease,” describing it as a distinct presenile form of dementia characterized by the plaques and tangles Alzheimer had reported.1PubMed Central. The discovery of Alzheimer’s disease
That single textbook entry is where the name “Alzheimer’s disease” was born. Because Kraepelin’s book was the definitive reference in the field, the term spread rapidly through academic psychiatry and neurology. The naming was an act of considerable institutional authority: Kraepelin chose to honor his pupil by attaching Alzheimer’s name to the condition.3PubMed Central. Alois Alzheimer: a hundred years after the discovery of the eponymous disorder
Kraepelin’s motivations have been debated by historians ever since. Some see a straightforward act of scientific credit. Others have suggested that Kraepelin had strategic reasons for carving out a new disease category. His clinic in Munich was competing for prestige and funding with other German psychiatric institutions. Naming a new disease after one of his researchers, based on work done in his own laboratory, reinforced Munich’s position as the center of cutting-edge brain research. Whether the motivation was purely collegial, partly political, or some combination of both, the result was the same: a disease that might otherwise have remained a footnote in a regional psychiatry conference became one of the most recognized medical terms in the world.
The Researchers History Largely Forgot
Alzheimer was not the only scientist examining these brain changes around the same time, and the decision to attach his name alone to the disease has drawn criticism for over a century. In 1907, the same year Alzheimer published his written report on Auguste Deter, a Czech neurologist named Oskar Fischer independently described neuritic plaques in the brains of 12 patients with senile dementia. Fischer’s sample was larger, and his descriptions of the plaques were detailed and systematic. These were landmark findings in dementia research, because they helped delineate the clinical and pathological entity we now call Alzheimer’s disease.4PubMed Central. Oskar Fischer and the study of dementia
Fischer worked in Prague under Arnold Pick, another major figure in dementia research. He lacked Kraepelin’s institutional backing, and his contributions were gradually overshadowed by the Munich group. His career was cut short by the Nazis; Fischer, who was Jewish, died in the Theresienstadt concentration camp in 1942. Only in recent decades has his role been seriously reassessed by historians of neuroscience.
Another overlooked figure is Gaetano Perusini, an Italian neuropathologist who worked in Alzheimer’s Munich laboratory and contributed additional case studies and pathological descriptions that helped build the early evidence base for the disease. Alzheimer himself credited Perusini’s work, titling a chapter of a 1911 publication “The Perusini cases.” In Italy, the condition is still sometimes referred to as “la malattia di Alzheimer-Perusini” in recognition of his contributions.5PubMed. Alzheimer-Perusini disease: the 100th anniversary of Gaetano Perusini’s publication Perusini died in 1915, killed during World War I at the age of 36, leaving behind a body of work that never received wide international recognition.
Solomon Carter Fuller, an African-American psychiatrist and neuropathologist, was another early contributor. Fuller was one of five research assistants chosen by Alzheimer to work in his Munich laboratory, an experience that shaped his subsequent research career. He went on to conduct his own studies of dementia pathology and published independently on the topic, yet his contributions went largely unrecognized for most of the twentieth century.6PubMed Central. Recognizing African-American contributions to neurology: The role of Solomon Carter Fuller (1872-1953) in Alzheimer’s disease research
The pattern is clear enough: the naming of a disease after a single individual inevitably flattens the contributions of the wider group of researchers who made the discovery possible. Alzheimer himself was a careful and collaborative scientist, but the eponym created an illusion of sole authorship that has taken over a century to partially correct.
When “Alzheimer’s” Almost Meant Something Else
For most of the twentieth century, “Alzheimer’s disease” did not mean what it means today. Kraepelin had defined it narrowly as a presenile condition, meaning dementia that struck before old age, roughly before 65. If the same symptoms and the same brain pathology appeared in a 75-year-old, it was called “senile dementia” and treated as a separate, less interesting phenomenon, just an expected consequence of growing old. This distinction between presenile and senile dementia persisted in textbooks and diagnostic practice for decades.
The problem was that the distinction rested on an arbitrary age cutoff, not on any real biological difference. As more brains were examined, the plaques and tangles looked the same whether the patient was 52 or 82. By the 1970s, researchers began arguing forcefully that Alzheimer’s disease and senile dementia were a single process and should be considered a single disease.7JAMA Neurology. The Prevalence and Malignancy of Alzheimer Disease: A Major Killer This was not just an academic reclassification. If the two conditions were unified, then Alzheimer’s disease was not a rare curiosity affecting a handful of middle-aged patients. It was a leading cause of death and disability in the elderly population.
That unification, which gained broad acceptance by the 1980s, transformed the scale and urgency of the disease. Funding agencies, advocacy groups, and the general public all needed a name for this newly recognized epidemic of cognitive decline. “Alzheimer’s disease” was already in the medical lexicon, so it expanded to fill the larger category. The name Kraepelin had coined for a narrow condition in 1910 came to encompass the vast majority of dementia cases worldwide. The term “senile dementia” gradually fell out of professional use, and “Alzheimer’s” became synonymous with the kind of progressive memory loss and confusion that millions of families recognized in their aging relatives.
What Happened When Scientists Went Back to Auguste D
The original brain slides from Auguste Deter were long thought to be lost. Then, in 1993, researchers in Munich rediscovered them in storage, still in usable condition. Reexamination of the specimens with modern techniques confirmed the presence of plaques and tangles, though one finding drew particular attention: some of the pathological features that had once been considered separate processes turned out to represent different stages of the same underlying disease progression.1PubMed Central. The discovery of Alzheimer’s disease
Researchers also extracted DNA from Deter’s preserved tissue and looked for genetic mutations associated with early-onset Alzheimer’s. Because she developed symptoms so young, a reasonable hypothesis was that she carried one of the known familial mutations in genes like presenilin 1, presenilin 2, or the amyloid precursor protein gene. The results were surprising: extended sequencing revealed no indication of any known familial Alzheimer’s mutation in those genes.8PubMed. A presenilin 1 mutation in the first case of Alzheimer’s disease: revisited This means the very first patient identified with the disease did not carry the kinds of genetic defects that researchers later pinpointed in families with inherited forms of early-onset Alzheimer’s. Her case may have been sporadic, driven by unknown risk factors rather than a single catastrophic gene mutation. It is a humbling reminder that even after more than a century of research, the biology of individual cases can still confound expectations.
Why We Still Use Eponyms in Medicine
Medical naming conventions have shifted over the decades. Many conditions once known by the name of their discoverer have been renamed to reflect the underlying biology. Diseases are increasingly described by their genetic cause, their molecular mechanism, or their clinical presentation rather than by the person who first wrote about them. Yet “Alzheimer’s disease” shows no signs of fading. The term is embedded in public awareness, research infrastructure, funding legislation, and advocacy organizations worldwide.
Eponyms remain remarkably common in neurology specifically. An analysis of neurologist-authored publications found that roughly one in five papers used at least one eponym in their title or abstract, a rate that held steady over a 25-year period. The total number of unique eponyms appearing in the neurological literature actually increased over time, and trainees surveyed about the practice overwhelmingly said that historical precedent, pervasiveness, and ease of use would keep eponyms alive in the field.9Neurology. Eponyms are here to stay: Usage in the literature and among current neurology trainees
There are real drawbacks to naming diseases after people. Eponyms carry no information about what the disease actually does or how it works. They can obscure the contributions of other researchers, as happened with Fischer, Perusini, and Fuller. And they sometimes honor figures whose broader conduct was questionable, though that particular criticism does not apply to Alzheimer, who by all accounts was a conscientious and humane clinician. The strongest argument for keeping “Alzheimer’s disease” is practical: everyone knows what it means. Replacing it with a descriptive term like “amyloid-tau neurodegeneration” would sacrifice decades of public understanding for the sake of taxonomic purity, and patients and families dealing with the condition have far more pressing concerns than what it is called.
How a Name Shaped Public Understanding
Before the unification of presenile and senile dementia in the 1970s and 1980s, severe memory loss in old age was widely regarded as a normal, inevitable part of aging. Families coped with it privately, and there was little public pressure for research funding or treatment development. Giving the condition a medical name changed that. “Alzheimer’s disease” reframed what had been dismissed as “just getting old” into a specific, diagnosable illness with a biological basis. The term has been in continuous use for over a hundred years since Kraepelin introduced it in 1910.10PubMed Central. History of Alzheimer’s Disease
That reframing had enormous practical consequences. It enabled the creation of dedicated research funding streams, specialized clinical trials, caregiver support networks, and public health campaigns. The name gave advocacy groups something concrete to rally around. The Alzheimer’s Association, founded in 1980, grew into one of the largest disease-specific nonprofit organizations in the world. None of that would have been possible if the condition were still filed under the vague heading of senility.
The name also carries weight that goes beyond medicine. When a relative receives an Alzheimer’s diagnosis, the word itself communicates gravity, progression, and the need for planning in a way that “dementia” alone sometimes does not. For better or worse, the eponym has become shorthand for a particular kind of loss, both for the person experiencing it and for those around them. The irony, of course, is that Auguste Deter could not remember her own name, and Alois Alzheimer could not have predicted that his would become one of the most recognized in all of medicine.